- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2065–2088
of 12,556
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bipolar Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
- Interventions
- FOR46, Enzalutamide, Pegfilgrastim, Blood Samples
- Biological · Drug · Procedure
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hodgkin Lymphoma
- Interventions
- Ruxolitinib, Nivolumab
- Drug
- Lead sponsor
- Veronika Bachanova
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 3 more
- Conditions
- Acne Vulgaris
- Interventions
- drospirenone and ethinyl estradiol, Placebo tablet
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Musculoskeletal Manipulations, Shoulder, Range of Motion, Muscle Strength, Surface Electromyography
- Interventions
- Thoracic Manipulation, Cervical Manipulation, glenohumeral posterior glide mobilization, Sleeper stretch
- Other
- Lead sponsor
- University of Hartford
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- West Hartford, Connecticut
- Conditions
- ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- MK-3795, Nivolumab, Cabozantinib, Bezlutifan
- Drug
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
- Conditions
- Relapsed/Refractory Aggressive B-Cell Lymphoma
- Interventions
- cemiplimab, odronextamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
- Conditions
- Bipolar Disorder
- Interventions
- aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Cancer
- Interventions
- multiple beams utilizing either intensity-modulated or 3D-conformal techniques
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- LY3295668 Erbumine, Endocrine therapy, Midazolam
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • San Antonio, Texas
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
- Interventions
- Alomfilimab, Atezolizumab
- Drug
- Lead sponsor
- Kymab Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
- Conditions
- Anterior Cruciate Ligament Injury
- Interventions
- Electrical Stimulation, Eccentric Exercise
- Device · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 14 Years to 35 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2011
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- Interventions
- Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
- Conditions
- Esophageal Cancer
- Interventions
- cisplatin, paclitaxel, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Degenerative Disc Disease(DDD)
- Interventions
- Circumferential Cervical Fusion (CCF), Anterior Cervical Discectomy and Fusion
- Device · Procedure
- Lead sponsor
- Providence Medical Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Paducah, Kentucky
- Conditions
- Ovarian Cancer, Advanced Malignant Solid Tumor
- Interventions
- Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII, Aldesleukin
- Drug · Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel, Tislelizumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cardiovascular Diseases
- Interventions
- aerobic exercise, resistance exercise, Combined resistance and aerobic exercise
- Behavioral
- Lead sponsor
- Iowa State University
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide
- Drug · Other · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Interventions
- AG-120, Nivolumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut